Exagen Management
Management criteria checks 2/4
Exagen's CEO is John Aballi, appointed in Oct 2022, has a tenure of 1.58 years. total yearly compensation is $931.95K, comprised of 56.3% salary and 43.7% bonuses, including company stock and options. directly owns 0.94% of the company’s shares, worth $222.07K. The average tenure of the management team and the board of directors is 1.6 years and 4.4 years respectively.
Key information
John Aballi
Chief executive officer
US$932.0k
Total compensation
CEO salary percentage | 56.3% |
CEO tenure | 1.6yrs |
CEO ownership | 0.9% |
Management average tenure | 1.6yrs |
Board average tenure | 4.4yrs |
Recent management updates
Recent updates
Why Investors Shouldn't Be Surprised By Exagen Inc.'s (NASDAQ:XGN) 31% Share Price Plunge
Mar 26Analysts Have Made A Financial Statement On Exagen Inc.'s (NASDAQ:XGN) Annual Report
Mar 22Exagen Inc.'s (NASDAQ:XGN) Business And Shares Still Trailing The Industry
Jul 21Exagen appoints John Aballi as CEO
Oct 17Analysts Just Slashed Their Exagen Inc. (NASDAQ:XGN) EPS Numbers
Aug 10Exagen (NASDAQ:XGN) Has Debt But No Earnings; Should You Worry?
Jul 26Is Exagen (NASDAQ:XGN) Weighed On By Its Debt Load?
Apr 05Does Exagen (NASDAQ:XGN) Have A Healthy Balance Sheet?
Dec 03Does Exagen (NASDAQ:XGN) Have A Healthy Balance Sheet?
Aug 06Exagen Inc.'s (NASDAQ:XGN) Intrinsic Value Is Potentially 62% Above Its Share Price
Apr 07Is Exagen (NASDAQ:XGN) Using Too Much Debt?
Mar 03Exagen issues preliminary testing revenue ahead of ICT chat
Jan 11Would Shareholders Who Purchased Exagen's (NASDAQ:XGN) Stock Year Be Happy With The Share price Today?
Jan 05Exagen (XGN) Investor Presentation - Slideshow
Nov 20CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | US$932k | US$525k | -US$24m |
Sep 30 2023 | n/a | n/a | -US$32m |
Jun 30 2023 | n/a | n/a | -US$35m |
Mar 31 2023 | n/a | n/a | -US$45m |
Dec 31 2022 | US$1m | US$111k | -US$47m |
Compensation vs Market: John's total compensation ($USD931.95K) is above average for companies of similar size in the US market ($USD674.46K).
Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.
CEO
John Aballi (38 yo)
1.6yrs
Tenure
US$931,950
Compensation
Mr. John Aballi serves as President, Chief Executive Officer and Director at Exagen Inc. since October 17, 2022. Most recently he served as SVP, General Manager, Urology & CLIA COO at Veracyte Inc. Mr. Aba...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Executive Chairman of the Board of Directors | 4.8yrs | US$132.81k | 0% $ 0 | |
CEO, President & Director | 1.6yrs | US$931.95k | 0.94% $ 222.1k | |
CFO & Corporate Secretary | 6.9yrs | US$915.09k | 0.30% $ 71.6k | |
Investors Relations Officer | no data | no data | no data | |
Senior Vice President of Sales and Marketing | 10.5yrs | no data | no data | |
Chief Innovation Officer & Member of Rheumatoid Arthritis Scientific Advisory Board | 1.6yrs | no data | no data | |
Chief Medical Officer | less than a year | no data | no data |
1.6yrs
Average Tenure
54yo
Average Age
Experienced Management: XGN's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Executive Chairman of the Board of Directors | 4.8yrs | US$132.81k | 0% $ 0 | |
CEO, President & Director | 1.6yrs | US$931.95k | 0.94% $ 222.1k | |
Chief Innovation Officer & Member of Rheumatoid Arthritis Scientific Advisory Board | 4.4yrs | no data | no data | |
Member of Breast Cancer Advisory Board | no data | no data | no data | |
Member of Breast Cancer Advisory Board | no data | no data | no data | |
Independent Director | 4.8yrs | US$33.75k | no data | |
Member of Breast Cancer Advisory Board | no data | no data | no data | |
Independent Director | 15.8yrs | US$80.70k | 0% $ 0 | |
Member of Breast Cancer Advisory Board | no data | no data | no data | |
Member of Breast Cancer Advisory Board | no data | no data | no data | |
Chairman of Scientific Advisory Board | 4.4yrs | US$130.00k | no data | |
Independent Director | 2.9yrs | US$82.70k | 0% $ 0 |
4.4yrs
Average Tenure
64yo
Average Age
Experienced Board: XGN's board of directors are considered experienced (4.4 years average tenure).